Summit, NJ - These are exciting times for Celgene and promising times for the patients we serve. We continue to deliver on multiple opportunities, translating the potential of transformational science into disease-altering and life-enhancing innovative medicines with the goal of helping patients with critical unmet medical needs worldwide live longer and better lives. This dedication to patients is aligned with our corporate vision, mission and values and reflects our unwavering commitment to put patients first. By advancing the course of healthcare through bold scientific pursuits and medical innovation we are making it possible for societies to progress and economies to prosper.
With our growing portfolio of innovative therapies, we are serving more patients, with new products and additional indications, in countries throughout the world. We are working to ensure that patients have access to our new innovative oral medicine POMALYST® (IMNOVID® in Europe) for third line treatment of multiple myeloma. Celgene’s ABRAXANE® is now approved for patients with metastatic pancreatic cancer. And we are also now serving patients in the field of Immunology and Inflammation with the introduction of OTEZLA®, an innovative oral treatment for patients with psoriasis and psoriatic arthritis. We continue to research and invest, advancing our own discoveries and scanning the landscape for opportunities to enhance and expand our deep and diverse portfolio of next-generation medicines that hold the potential to change the course of human health.
We currently have 22 clinical development programs, with about 28,000 patients enrolled in more than 100 Celgene-sponsored clinical trials. At the same time we are mindful that Celgene is part of an ecosystem of innovation. Our research and discovery efforts seek to collaborate with and complement the work of medical and academic institutions of excellence, government agencies and regulators, patient advocacy groups and non-governmental organizations, as well as investors and other biopharmaceutical companies.
A strong commitment to five pillars of corporate responsibility permeate our global organization: patients and communities, commitment to safety, governance, global health and environment and sustainability. Let me cite just a few highlights. Our commitment to patients extends beyond our innovative life-enhancing therapies to our pioneering patient access programs. Our Patient Support Coordinators work tirelessly to help patients gain access to the treatments they need. More than 20,000 patients have received assistance from Celgene Patient Support since 2007.
Our giving centers on patient-focused programs such as the Leukemia and Lymphoma Society’s Light the Night walks, where Celgene ranked first among biopharmaceutical companies, and the Pancreatic Cancer Action Network’s Purple Strides campaign. Our focus also extends to supporting science education through our participation in programs like Change the Equation, as well as scholarships and fellowships to help train the next generation great minds in the life sciences.
For the complete report and more: http://assets1.celgene.com/content/uploads/celgene-responsibility.pdf
We currently have 22 clinical development programs, with about 28,000 patients enrolled in more than 100 Celgene-sponsored clinical trials. At the same time we are mindful that Celgene is part of an ecosystem of innovation. Our research and discovery efforts seek to collaborate with and complement the work of medical and academic institutions of excellence, government agencies and regulators, patient advocacy groups and non-governmental organizations, as well as investors and other biopharmaceutical companies.
A strong commitment to five pillars of corporate responsibility permeate our global organization: patients and communities, commitment to safety, governance, global health and environment and sustainability. Let me cite just a few highlights. Our commitment to patients extends beyond our innovative life-enhancing therapies to our pioneering patient access programs. Our Patient Support Coordinators work tirelessly to help patients gain access to the treatments they need. More than 20,000 patients have received assistance from Celgene Patient Support since 2007.
Our giving centers on patient-focused programs such as the Leukemia and Lymphoma Society’s Light the Night walks, where Celgene ranked first among biopharmaceutical companies, and the Pancreatic Cancer Action Network’s Purple Strides campaign. Our focus also extends to supporting science education through our participation in programs like Change the Equation, as well as scholarships and fellowships to help train the next generation great minds in the life sciences.
For the complete report and more: http://assets1.celgene.com/content/uploads/celgene-responsibility.pdf
